Filtered By:
Drug: Docetaxel

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 178 results found since Jan 2013.

Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment
Drug Deliv. 2022 Dec;29(1):889-905. doi: 10.1080/10717544.2022.2050845.ABSTRACTAs there is currently no effective therapy for patients with prostate cancer (PCa) bone metastasis, it was stringent to explore the relevant treatment strategies. Actually, the interaction between cancer cells and bone microenvironment plays important role in prostate cancer bone metastasis, especially the Sonic hedgehog protein (SHH) signaling in the bone microenvironment. The SHH promotes osteoblast maturation and osteoblast then secretes RANKL to induce osteoclastogenesis. Herein, this study develops bone-targeting calcium phosphate lipid hyb...
Source: Drug Delivery - March 14, 2022 Category: Drugs & Pharmacology Authors: Xiangyu Zhang Qingbin Liu Tingting Zhang Pei Gao Hui Wang Lu Yao Jingwen Huang Shulong Jiang Source Type: research

Self-assembled nanocomposites of carboxymethyl β-dextran/protamine sulfate for enhanced chemotherapeutic drug sensitivity of triple-negative breast cancer by autophagy inhibition via a ternary collaborative strategy
In this study, a tri-drug nanocomposite (NP) delivery system was devised using carboxymethyl β-dextran (CMD) and protamine sulfate (PS), two natural materials with good bio-compatibility. They were designed to carry the chemotherapeutic drug docetaxel (DTX), the autophagy inhibitor chloroquine (CQ), and Atg5 siRNA to cancer cells. The CQ + DTX + Atg5 siRNA NPs was driven by electrostatic interaction and self-assembly methods. The breast cancer cell line MDA-MB-231 was used for both cell culture and establishing mouse xenograft model. Our findings demonstrated that CQ and Atg5 siRNA encapsulated in NPs could enhance the se...
Source: International Journal of Biological Macromolecules - February 13, 2023 Category: Biochemistry Authors: Yunhao Li Fan Jia Yujuan Gao Xuan Wang Xinyue Cui Zian Pan Weifeng Wang Mingjun Li Jianqing Lu Yan Wu Source Type: research

Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma
Highlights: ► HORMAD1 is a cancer/testis antigen expressed exclusively in germ cells during normal development. ► HORMAD1 is expressed in a substantial portion of human epithelial ovarian cancers. ► HORMAD1 down-regulation affected tumor growth in mouse models of human ovarian cancer.Abstract: The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invas...
Source: Cancer Letters - July 30, 2012 Category: Cancer & Oncology Authors: Mian M.K. Shahzad, Yong-Hyun Shin, Koji Matsuo, Chunhua Lu, Masato Nishimura, De-Yo Shen, Yu Kang, Wei Hu, Edna M. Mora, Cristian Rodriguez-Aguayo, Arvinder Kapur, Justin Bottsford-Miller, Gabriel Lopez-Berestein, Aleksandar Rajkovic, Anil K. Sood Tags: Mini-reviews Source Type: research

The Role of Hypoxia-Inducible Factor-1α and -2α in Androgen Insensitive Prostate Cancer Cells
Conclusions: Our results demonstrate that HIF-1α and -2α are important for cell proliferation and invasion ability in prostate cancer. Together, our results indicate that combinations of target agents with HIF knockdown may represent a promising strategy for the treatment of prostate cancer.
Source: Urologic Oncology: Seminars and Original Investigations - April 27, 2012 Category: Urology & Nephrology Authors: Chang Wook Jeong, Cheol Yong Yoon, Seong Jin Jeong, Sung Kyu Hong, Seok-Soo Byun, Cheol Kwak, Sang Eun Lee Tags: Clinical - Prostate Source Type: research

Abstract 731: SRI-28731, a highly potent and selective MAP4K4 (HGK) inhibitor for cancer therapy
MAP4K4, a Ser/Thr kinase, was identified as an important pro-migratory kinase in an siRNA screen, targeting 5,234 human genes for modulators of tumor cell motility. MAP4K4 siRNA potently suppressed cell invasion and migration of multiple cancer cell lines, indicating a broad role in cell motility. There are no drugs in the clinic that are known to specifically target MAP4K4 for cancer therapy. We have successfully developed an orally active, highly effective and selective MAP4K4 inhibitor (SRI-28731) with potent in vitro and in vivo anticancer activity. SRI-28731 is more potent than Paclitaxel (Taxol) against most of the b...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Chang, C.-T., Park, J., Zhou, W., Liu, X., Sato, B., Dinh, D., Furimsky, A., Beviglia, L., Sambucetti, L., Jong, L. Tags: Experimental and Molecular Therapeutics Source Type: research

Hypoxia-induced STAT3 Contributes to Chemoresistance and Epithelial-Mesenchymal Transition in Prostate Cancer Cells.
This study suggests a new rationale for inhibiting cancer chemoresistance and EMT under hypoxia using anti-STAT3 strategies. PMID: 25701777 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - February 18, 2015 Category: Biochemistry Authors: Liu ZQ, Han YC, Fang JM, Hu F, Zhang X, Xu Q Tags: Biochem Biophys Res Commun Source Type: research

Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines.
Authors: Yuan TM, Liang RY, Chueh PJ, Chuang SM Abstract The identification of prognostic markers and establishing their value as therapeutic targets improves therapeutic efficacy against human cancers. Ribophorin II (RPN2) has been demonstrated to be a prognostic marker of human cancer, including breast and pancreatic cancers. The present study aimed to evaluate RPN2 expression in gastric cancer and to examine the possible correlation between RPN2 expression and the response of cells to clinical anticancer drugs, which has received little research attention at present. The gastric cancer AGS, TMC-1, SNU-1, TMK-1, ...
Source: Oncology Letters - June 4, 2015 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.
In conclusion, development of a novel 3D cell culture model of prostate cancer bone metastasis has been initiated resulting, for the first time, in the successful delivery of gene therapeutics in a 3D in vitro model. Further enhancement of this model will help elucidate the pathogenesis of prostate cancer and also accelerate the design of effective therapies which can penetrate into the bone microenvironment for prostate cancer therapy. PMID: 26196533 [PubMed - as supplied by publisher]
Source: Biomaterials - July 14, 2015 Category: Materials Science Authors: Fitzgerald KA, Guo J, Tierney EG, Curtin CM, Malhotra M, Darcy R, O'Brien FJ, O'Driscoll CM Tags: Biomaterials Source Type: research

Abstract 730: The role of ZEB1/ZEB2 and {beta}III-tubulin in mediating docetaxel-resistant prostate cancer
Docetaxel therapy is the gold standard treatment for advanced castrate-resistant prostate cancer (CRPC). However, patients either do not respond or develop resistance over time. Transcriptomic and proteomic analysis of docetaxel-resistant prostate cancer sub-lines developed by our group revealed multiple mechanisms of resistance in line with advanced disease, including over-expression of anti-apoptotic proteins and alterations of NF-KB activation. The sub-lines also demonstrated a coordinated loss and gain of epithelial and mesenchymal markers respectively; a process characteristic of Epithelial-Mesenchymal Transition (EMT...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Hanrahan, K., Prencipe, M., Bugler, J., Murphy, L., O'Neill, A., Watson, R. W. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 4678: A novel nuclear transporter for androgen receptor and AR-variant-7 in castration resistant prostate cancer: Ideal therapeutic target
Conclusions: We identified novel (i) transporter of AR and (ii) approach for treating CRPC in men.Citation Format: Aijaz Parray, Hifzur R. Siddique, Alyssa Langfald, Pooja Singh, Mikihiko Naito, Robert Matusik, Ingo Schmitz, Shahriar Koochekpour, Badrinath R. Konety, Mohammad Saleem. A novel nuclear transporter for androgen receptor and AR-variant-7 in castration resistant prostate cancer: Ideal therapeutic target. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4678. ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Parray, A., Siddique, H. R., Langfald, A., Singh, P., Naito, M., Matusik, R., Schmitz, I., Koochekpour, S., Konety, B. R., Saleem, M. Tags: Endocrinology Source Type: research

Enhancement of Chemosensitivity by Stathmin-1 Silencing in Gastric Cancer Cells In Situ and In Vivo.
Authors: Meng ZJ, Tao K Abstract Reports show that the stathmin gene may have a close relationship with tumor chemotherapeutic sensitivity. However, the effect of stathmin-1 on the chemosensitivity of gastric cancer to docetaxel has not been clearly determined. siRNA targeting stathmin-1 was introduced. The cell growth inhibition, expression of associated proteins, cell cycle, and apoptosis were evaluated by MTT, Western blot, and flow cytometric assays, respectively. The influence of silencing stathmin-1 was detected in situ and in vivo. SGC7901/docetaxel cells are the drug-resistant cells. After silencing stathmi...
Source: Oncology Research - January 24, 2016 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Livin enhances chemoresistance in head and neck squamous cell carcinoma.
In conclusion, our results suggest that siRNA-mediated Livin knockdown enhanced the chemosensitivity of the three HNSCC cell lines to cisplatin, 5-FU and docetaxel. Although further investigations are required to support these findings, our results demonstrated that novel therapeutic strategies with combined use of siRNA targeting Livin and chemotherapeutic agents may have applications in the treatment of advanced HNSCC. PMID: 28440463 [PubMed - as supplied by publisher]
Source: Oncology Reports - April 27, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research